Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 16, 2012, Pages 2257-2268

  Inoue, Masahiro ^a  

^a AIKI Bldg   (Japan)

Author keywords

diabetes; glucose; insulin; mitiglinide; postprandial; voglibose

Indexed keywords

FATTY ACID; GLUCAGON; GLUCOSE; INSULIN; LIPID; MITIGLINIDE; TRIACYLGLYCEROL; VOGLIBOSE; WATER;

ADULT; BLOOD PRESSURE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DRUG EFFECT; DRUG SAFETY; FATTY ACID BLOOD LEVEL; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESPONSE; JAPANESE; LABORATORY TEST; LIPID BLOOD LEVEL; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; TEST MEAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FEMALE; GLUCAGON; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INOSITOL; INSULIN; ISOINDOLES; MALE; MIDDLE AGED;

EID: 84867648767     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.726614     Document Type: Review

References (40)

1. Monnier L, Colette C, Dunseath GJ, et al. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007;30:263-9
2. DECODE Study Group; European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. The DECODE-study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe. Diabetologia 1999;42:647-54
3. Qiao Q, Nakagami T, Tuomilehto J, et al. Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia 2000;43:1470-5
4. Hanefeld M, Fischer S, Schmechel H, et al. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 1991;14:308-17
5. Del Prato S. In search of normoglycaemia in diabetes: Controlling postprandial glucose. Int J Obes Relat Metab Disord 2002;26(Suppl 3):S9-S17
6. Esposito K, Ciotola M, Carleo D, et al. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab 2008;93:1345-50
7. International Diabetes Federation. 2011 guideline for management of postmeal glucose in diabetes. International Diabetes Federation; Brussels: 2011
8. Vichayanrat A, Ploybutr S, Tunlakit M, et al. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res Clin Pract 2002;55:99-103
9. Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus: A randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009;373:1607-14
10. Malaisse WJ. Mitiglinide: A rapidand short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients. Expert Opin Pharmacother 2008;9:2691-8
11. Gao X. Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. J Int Med Res 2009;37:812-21
12. Konya H, Miuchi M, Konishi K, et al. Pleiotropic effects of mitiglinide in type 2 diabetes mellitus. J Int Med Res 2009;37:1904-12
13. Phillippe HM, Wargo KA. Mitiglinide: A novel agent for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2010;44:1615-23
14. Abe M, Okada K, Maruyama T, et al. Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother 2010;11:169-76
15. Kaku K, Tanaka S, Origasa H, et al. Concomitant effects of a rapid and short acting insulin secretagogue mitiglinide in type 2 diabetes patients with inadequate control of blood glucose with voglibose monotherapy -Phase II/III double blind comparative study. Jpn Pharmacol Ther 2007;35:S51-72; In Japanese An early study showing the clinical benefits of using mitiglinide in combination with voglibose.
16. Katsuno T, Watanabe N, Nagai E, et al. Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus. J Diabetes Investig 2011;2:204-9
17. Toh Y, Origasa H, Akanuma Y. Clinical pharmacological study of mitiglinide in type 2 diabetes patients with voglibose monotherapy. Jpn Pharmacol Ther 2007;35:S39-49; In Japanese
18. Pharmaceutical and Medical Devices Agency. Deliberation Report. March 23, 2011 (Voglibose/Mitiglinide Combination Tablets). 2011
19. Yoshino G, Tominaga M, Hirano T, et al. The test meal A: A pilot model for the international standard of test meal for an assessment of both postprandial hyperglycemia and hyperlipidemia. J Japan Diab Soc 2006;49:361-71; In Japanese
20. Narita T, Yokoyama H, Yamashita R, et al. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes Obes Metab 2012;14:283-7
21. Hiki M, Shimada K, Kiyanagi T, et al. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease -Juntendo University Trial: Effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH). Circ J 2010;74:1471-8
22. A clinical trial of compound drugs for patients with type 2 diabetes -Comparative analysis of the characteristics of postprandial hyperglycemia improving drugs for postprandial metabolic disorder (UMIN000006199). Tokyo, Japan: UMIN-CTR Clinical Trial Registry. Available from: Https://upload.umin.ac. jp/cgi-open-bin/ctr/ctr.cgi? function=brows&action=brows&recptno= R000007330&type=summary&language=E [Last accessed 20 July 2012]
23. Fukase N, Takahashi H, Manaka H, et al. Effects of AO-128, alpha-glucosidase inhibitor on secretion of gastric inhibitory polypeptide and truncated glucagon-like peptide-1. Clin Rep 1991;25:4801-7; In Japanese
24. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Investig 2012;3:39-40
25. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19
26. Keskin M, Kurtoglu S, Kendirci M, et al. Homeostasis model assessment is more reliable than the fasting glucose/ insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005;115:e500-3
27. Phillips DI, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: Comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 1994;11:286-92
28. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22:920-4
29. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002;359:2072-7
30. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: An expert panel statement. Curr Vasc Pharmacol 2011;9:258-70
31. Nordestgaard BG, Freiberg JJ. Clinical relevance of non-fasting and postprandial hypertriglyceridemia and remnant cholesterol. Curr Vasc Pharmacol 2011;9:281-6
32. Uchino H, Niwa M, Shimizu T, et al. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: Assessment using nateglinide, a new insulin secretagogue. Endocr J 2000;47:639-41
33. Moritoh Y, Takeuchi K, Hazama M. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J Pharmacol Exp Ther 2009;329:669-76
34. Shigeto M, Katsura M, Matsuda M, et al. Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-dependent protein kinase family. J Pharmacol Sci 2008;108:274-8
35. Knop FK, Aaboe K, Vilsbøll T, et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab 2012;14:500-10
36. Mori Y, Ojima K, Akabane K, et al. Effect of combination therapy with mitiglinide and voglibose on glucose increases and changes in insulin dynamics after sucrose loading in spontaneously diabetic OLETF rats. Ther Res 2011;32:1475-82; In Japanese
37. Johanson EH, Jansson PA, Gustafson B, et al. No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes. Diabetes Metab Res Rev 2005;21:376-81
38. Mori Y, Kuriyama G, Tajima N. Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test. Endocrine 2004;25:203-6
39. Uchida D, Nakamura S, Yamane T, et al. Evaluation of miglitol and voglibose effect on postprandial plasma glucose after test meal A loading. J Japan Diab Soc 2008;51:411-8; In Japanese
40. Twickler TB, Dallinga-Thie GM, Cohn JS, et al. Elevated remnant-like particle cholesterol concentration: A characteristic feature of the atherogenic lipoprotein phenotype. Circulation 2004;109:1918-25